News

KZR-616 Shows Early Promise in Treatment of Active SLE

KZR-616, a selective immunoproteasome inhibitor, is safe, well-tolerated, and effectively reduces disease activity in patients with active systemic lupus erythematosus (SLE), preliminary Phase 1b data show. The findings were presented at the European League Against Rheumatism (EULAR) 2019 Annual Meeting in Geneva, Switzerland, in a poster titled, “…

Aurinia Launches Lupus Awareness Campaigns with Support Initiatives

In observance of World Lupus Day and Lupus Awareness Month, Aurinia Pharmaceuticals has announced disease awareness and educational initiatives aimed at supporting patients with lupus nephritis, a serious complication of systemic lupus erythematosus (SLE). World Lupus Day was May 10, and Lupus Awareness Month is marked…